Management of patients that relapse after rituximab-based therapy. For patients who relapse after ibrutinib or discontinue ibrutinib for reasons such as toxicity, there are limited data, and venetoclax or anti-CD20 monoclonal antibody with chemotherapy or proteasome inhibitors may be considered, depending on the availability of venetoclax and other drugs.